Gene · 26524
Papers2,966
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 2,966
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Hippo signaling pathway in cervical cancer: insights into mechanisms and therapeutic potential. | Front Oncol | 2025 | 41256331 | PubTator, text mining | PubMed |
| Overexpressed miR-135b in the ovaries of PCOS promotes granulosa cell proliferation by inhibiting Hippo signaling pathway. | J Assist Reprod Genet | 2025 | 41045336 | PubTator, text mining | PubMed |
| TNF promotes osteoclastogenesis by secreting miR-31-5p into small extracellular vesicles via the autotaxin-LPA-LPAR1 axis in arthritic fibroblast-like synoviocytes. | Arch Biochem Biophys | 2025 | 41043572 | PubTator, text mining | PubMed |
| Integration of Circulating miR-31-3p and miR-196a-5p as Liquid Biopsy Markers in HPV-Negative Primary Laryngeal Squamous Cell Carcinoma. | Diseases | 2025 | 41002715 | PubTator, text mining | PubMed |
| The m6A modification in cancer: roles, implications, and its potential in therapy. | Mol Biomed | 2025 | 40986143 | PubTator, text mining | PubMed |
| SARS-CoV-2 NSP13 interacts with TEAD to suppress Hippo-YAP signaling. | Elife | 2025 | 40985618 | PubTator, text mining | PubMed |
| Targeting developmental vulnerabilities in childhood sarcomas. | Cancer Metastasis Rev | 2025 | 40983796 | PubTator, text mining | PubMed |
| [Expression of Concern] miR‑135b, upregulated in breast cancer, promotes cell growth and disrupts the cell cycle by regulating LATS2. | Int J Oncol | 2025 | 40970336 | PubTator, text mining | PubMed |
| iPSC-based drug discovery identified the Hippo signaling pathway as a therapeutic target in the fibrosis of NPHP1-deficient nephronophthisis. | Stem Cell Res Ther | 2025 | 40968381 | PubTator, text mining | PubMed |
| STK4 inhibits the E3 activity of HOIP by phosphorylating its allosteric ubiquitin-binding site. | Cell Discov | 2025 | 40957900 | PubTator, text mining | PubMed |
| Regulation of tension-dependent localization of LATS1 and LATS2 to adherens junctions. | bioRxiv | 2025 | 40909571 | PubTator, text mining | PubMed |
| Correction: Knockdown of PVT1 inhibits cell proliferation in luminal and basal-like breast cancer subtypes by activating LATS2/Hippo signaling pathway. | World J Surg Oncol | 2025 | 40883761 | PubTator, text mining | PubMed |
| Identifying potential miRNA-disease associations through an accurate matrix completion approach. | Brief Bioinform | 2025 | 40874820 | PubTator, text mining | PubMed |
| Biomolecular phase separation in tumorigenesis: from aberrant condensates to therapeutic vulnerabilities. | Mol Cancer | 2025 | 40849651 | PubTator, text mining | PubMed |
| The components and regulation of the Hippo pathway and its relationships with the progression and treatment of Non-small cell lung cancer (NSCLC). | Cancer Cell Int | 2025 | 40830878 | PubTator, text mining | PubMed |
| An efficient and interactive feature selection approach based on copula entropy for high-dimensional genetic data. | Sci Rep | 2025 | 40820100 | PubTator, text mining | PubMed |
| Physical activity and glioblastoma: a paradigm shift in neuro-oncology therapy. | Front Oncol | 2025 | 40809025 | PubTator, text mining | PubMed |
| Integration of HiMoRNA and RNAChrom: Validation of the Functional Role of Long Non-coding RNAs in the Epigenetic Regulation of Human Genes Using RNA-Chromatin Interactome Data. | Acta Naturae | 2025 | 40771853 | PubTator, text mining | PubMed |
| Discovery and Optimization of LATS1 and LATS2 Kinase Inhibitors for Use in Regenerative Medicine. | J Med Chem | 2025 | 40768682 | PubTator, text mining | PubMed |
| [Retracted] miR-372 promotes breast cancer cell proliferation by directly targeting LATS2. | Exp Ther Med | 2025 | 40746446 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/26524/papers?page=3